Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IndoVac COVID-19 Vaccine Booster Study
NCT05525208Phase 2Completed
- Sponsor
- Bio Farma
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of IndoVac in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Bio Farma. Primary endpoint: Immunogenicity of the candidate vaccine at 14 days. Started Sep 2022; status: completed.
02
Drugs
IndoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05525208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525208.